The Affinity Proteomics Units-Stockholm supports clinical researchers providing cutting edge affinity-based methods for protein quantification in body fluids.
Our equipment and expertise makes us capable to perform protein profiling of large sample cohorts and to contribute to biomarker studies from discovery to verification and validation.
We are part of the Biomarker platform within the European infrastructure for translational medicine (EATRIS).
We host a number of commercial platforms (PEA Olink, Simoa Quanterix, bead-based, Luminex, ecc) that we apply to offer commercial available assay kit upon request. However, we are also engaged in technological development, and we adapt our open platforms to develop novel methods and applications (eg. immunoassays for new candidate biomarkers not available in the market yet, detection of protein-protein interactions, virus particles, patients centric micro-sampling in line with ultra sensitive assays, ecc).
The development of new workflows and methods involves a number of inter-unit and inter-platforms collaboration at Scilifelab.
We collaborate with researchers in the technological fields and with companies to promote the translation of new biomarkers and technologies from the bench into practical applications and marketable products (eg. clinical trials, test of new device prototypes, ecc).